Clinicopathological characteristics | Negative N (%) 21 (38.9) | Positive N (%) 33 (61.1) | Significance | |
---|---|---|---|---|
Age years | Mean (SD) | 52.2 (7.8) | 49.8 (10) | t=0.87, p=0.391a |
Tumor stage (N=39) | T1/2 | 3 (30) | 7 (70) | p= 1b |
T3/4 | 9 (31) | 20 (69) | ||
L.N stage (N=28) | No | 6 (40) | 9 (60) | p=0.435b |
Yes | 3 (23.1) | 10 (76.9) | ||
M stage (N=36) | No | 10 (32.3) | 21 (67.7) | p= 1b |
Yes | 2 (40) | 3 (60) | ||
FIGO stage(N=38) | 1/2 | 2 (25) | 6 (75) | p= 1b |
3/4 | 10 (33.3) | 20 (66.7) | ||
Ascites (N=43) | No | 4 (23.5) | 13 (76.5) | X2=1.04, p= 0.307 |
Yes | 10 (38.5) | 16 (61.5) | ||
Residual tumor (N=39) | No | 10 (45.5) | 12 (54.5) | X2= 3.33, p=0.068 |
Yes | 3 (17.6) | 14 (82.4) | ||
Metastasis (N=39) | No | 6 (35.3) | 11 (64.7) | X2= 0.29, p=0.59 |
Yes | 6 (27.3) | 16 (72.7) | ||
Recurrence (N=38) | No | 7 (41.2) | 10 (58.8) | X2= 0.66, p=0.415 |
Yes | 6 (28.6) | 15 (71.4) | ||
Peritoneal deposits (N= 45) | No | 2 (22.2) | 7 (77.8) | p= 0.695b |
Yes | 13 (36.1) | 23 (63.9) | ||
Neoadjuvant therapy (N=35) | No | 10 (35.7) | 18 (64.3) | p=1b |
Yes | 2 (28.6) | 5 (71.4) | ||
Ki-67 (N=53) | Low | 11 (52.4) | 10 (47.6) | X2=2.367, p=0.124 |
High | 10 (31.2) | 22 (68.8) | ||
CEA (N=15) | Median (min-max) | 2.8 (0.6–8) | 2.1 (0.1–64) | Z=0, p=1c |
CA 125 (N=28) | Median (min-max) | 273 (170–1230) | 298 (7–1268) | Z= −0.92.533, p= 0.360c |